pharma news today glp-1 2025 A biopharmaceutical company is looking for ways to slim down household pets. Okava Pharmaceuticals, a San Francisco based company, is introducing a new clinical weight loss study for cats. MEOW-1, as 2025 marked a breakout year

In January 2026, the company announced a strategic initiative to expand its PharmaPatch microneedle patch platform into select therapeutic peptides

Full-service weight loss consultation, prescription, and semaglutide and tirzepatide injections to help you fast track your health goals

*Correspondence: Qilai Huang, [email protected] These authors contributed equally to this work This article was submitted to Cellular Biochemistry, a section of the journal Frontiers in Molecular Biosciences Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Orforglipron (Foundayo) is a more convenient option than GLP-1 injections, but is not as clinically effective as GLP-1 injections

Your gut made some this morning

Meets CMS-established body mass index (BMI) requirements